← Leaderboards
Jonathan A Fletcher
Dana-Farber Cancer Institute
$3,049,199
Attributed
$3,049,199
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,308,847 · 6
By mechanism
P50$9,308,847 · 5
P01$0 · 1
Top collaborators
- Scott Michael Schuetze3 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Cynthia Casson Morton$29,583,314
Others in their field
Top investigators on “Biological Markers”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,644,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$297,689,086
- Lawrence Corey · Fred Hutchinson Cancer Center$297,689,086
- David R. Weir · University Of Michigan At Ann Arbor$286,732,935
- Jeffrey P Krischer · University Of South Florida$271,114,178
- David Heimbrook · Leidos Biomedical Research, Inc.$227,381,786
Research focus
Biological MarkersGeneticInsightGenesCombined Modality TherapyResponseResistance MechanismMutationGenomicsMolecularValidationClinical TrialsPhosphotransferasesPre-ClinicalPreclinical StudyCellsEventNovel StrategiesCancer BiologyDiagnosisBiologicalBiopsyClinical ResearchBiochemical
Grant awards (16)
Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment$1,890,694
P50 · FY2025 · CA
PROJECT 1: Genomic Vulnerabilities in Leiomyosarcoma (LMS)$423,362
P50 · FY2025 · CA · contact PI
Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment$2,094,748
P50 · FY2024 · CA
PROJECT 1: Genomic Vulnerabilities in Leiomyosarcoma (LMS)$397,124
P50 · FY2024 · CA · contact PI
Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment$2,274,206
P50 · FY2023 · CA
PROJECT 1: Genomic Vulnerabilities in Leiomyosarcoma (LMS)$487,565
P50 · FY2023 · CA · contact PI
PROJECT 1: Genomic Vulnerabilities in Leiomyosarcoma (LMS)$463,494
P50 · FY2022 · CA · contact PI
Career Enhancement Program$91,989
P50 · FY2022 · CA · contact PI
Overcoming Resistance to KIT/PDGFRA Inhibition in GIST$260,282
P50 · FY2017 · CA · contact PI
Overcoming Resistance to KIT/PDGFRA Inhibition in GIST$243,027
P50 · FY2016 · CA · contact PI
Overcoming Resistance to KIT/PDGFRA Inhibition in GIST$249,214
P50 · FY2015 · CA · contact PI
Overcoming Resistance to KIT/PDGFRA Inhibition in GIST$240,296
P50 · FY2014 · CA · contact PI
Overcoming Resistance to KIT/PDGFRA Inhibition in GIST$192,846
P50 · FY2013 · CA · contact PI
CORE--MOLECULAR CYTOGENETICS$0
P01 · FY2002 · CA
CORE--MOLECULAR CYTOGENETICS$0
P01 · FY2001 · CA
CORE--MOLECULAR CYTOGENETICS$0
P01 · FY2000 · CA